Clinical trial • Phase III • Oncology
Clinical trial in Non-Hodgkin lymphoma|Chronic lymphocytic leukemia
Phase III trial for Non-Hodgkin lymphoma|Chronic lymphocytic leukemia. open-label. 65 participants.
Overview
- Trial Therapeutic Area
- Oncology
- Trial Disease
- Non-Hodgkin lymphoma|Chronic lymphocytic leukemia
- Trial Stage
- Phase III
Key dates
- Initial CTIS Submission Date
- 27-08-2024
- First CTIS Authorization Date
- 16-12-2024
Trial design
open-label Phase III trial across 20 sites in France, Poland, Greece and others.
- Open Label
- Yes
- Target Sample Size
- 65
- Trial Duration For Participant
- 730
Recruitment
- Planned Sample Size
- 65
- Recruitment Window Months
- 24
Geography
- Total Number Of Sites
- 20
- Total Number Of Participants
- 52
France
- Earliest CTIS Part Ii Submission Date
- 15-11-2024
- Latest Decision Or Authorization Date
- 14-04-2026
- Processing Time Days
- 515
- Number Of Sites
- 6
- Number Of Participants
- 5
Sites
- Site Name
- Institut Curie
- Department Name
- Unité d’Investigation Clinique Adulte
- Contact Person Name
- Clémentine SARKOZY
- Contact Person Email
- clementine.sarkozy@curie.fr
- Site Name
- Centre Hospitalier Universitaire De Lille
- Department Name
- Hopital Claude Huriez - Service des Maladies du sang
- Contact Person Name
- Franck MORSCHHAUSER
- Contact Person Email
- franck.morschhauser@chu-lille.fr
- Site Name
- Oncopole Claudius Regaud
- Department Name
- Institut Universitaire du Cancer I.U.C.Toulouse – Oncopôle Département Hématologie
- Contact Person Name
- Loïc Ysebaert
- Contact Person Email
- ysebaert.loic@iuct-oncopole.fr
- Site Name
- Centre Hospitalier Universitaire De Nantes
- Department Name
- Clinical Hematology
- Contact Person Name
- Benoit TESSOULIN
- Contact Person Email
- benoit.tessoulin@chu-nantes.fr
- Site Name
- Institut Paoli Calmettes
- Department Name
- Hematology Department
- Contact Person Name
- Robin NOEL
- Contact Person Email
- noelr@ipc.unicancer.fr
- Site Name
- Institut Gustave Roussy
- Department Name
- Département d’Innovations Thérapeutiques et d’essais Précoces (DITEP)
- Contact Person Name
- Vincent RIBRAG
- Contact Person Email
- vincent.ribrag@gustaveroussy.fr
Poland
- Earliest CTIS Part Ii Submission Date
- 15-11-2024
- Latest Decision Or Authorization Date
- 15-04-2026
- Processing Time Days
- 516
- Number Of Sites
- 4
- Number Of Participants
- 30
Sites
- Site Name
- Uniwersyteckie Centrum Kliniczne
- Department Name
- Osrodek Badan Klinicznych Wczesnych Faz
- Contact Person Name
- Jan Maciej Zaucha
- Contact Person Email
- jan.zaucha@gumed.edu.pl
- Site Name
- Pratia S.A.
- Department Name
- Pratia MCM
- Contact Person Name
- Wojciech Jurczak
- Contact Person Email
- rejestracja.mcm@pratia.com
- Site Name
- Aidport Sp. z o.o.
- Department Name
- Aidport Sp z o o
- Contact Person Name
- Michal Kwiatek
- Contact Person Email
- michal.kwiatek@aidport.pl
- Site Name
- Pratia Hematologia Sp. z o.o.
- Department Name
- Pratia Onkologia Katowice
- Contact Person Name
- Sebastian Grosicki
- Contact Person Email
- kontakt.onkologia.katowice@pratia.com
Greece
- Earliest CTIS Part Ii Submission Date
- 13-09-2024
- Latest Decision Or Authorization Date
- 15-04-2026
- Processing Time Days
- 579
- Number Of Sites
- 1
- Number Of Participants
- 1
Sites
- Site Name
- General Hospital Of Athens Alexandra
- Department Name
- Department of Clinical Therapeutics
- Contact Person Name
- Maria Gavriatopoulou
- Contact Person Email
- mgavria@med.uoa.gr
Belgium
- Earliest CTIS Part Ii Submission Date
- 15-11-2024
- Latest Decision Or Authorization Date
- 13-04-2026
- Processing Time Days
- 514
- Number Of Sites
- 1
- Number Of Participants
- 1
Sites
- Site Name
- Universitair Ziekenhuis Gent
- Department Name
- Hematology
- Contact Person Name
- Ciel De Vriendt
- Contact Person Email
- studies.hematologie@uzgent.be
Spain
- Earliest CTIS Part Ii Submission Date
- 04-06-2025
- Latest Decision Or Authorization Date
- 15-04-2026
- Processing Time Days
- 315
- Number Of Sites
- 8
- Number Of Participants
- 15
Sites
- Site Name
- Hospital Universitario Fundacion Jimenez Diaz
- Department Name
- Oncology department
- Contact Person Name
- Bernard Doger de Speville
- Contact Person Email
- bernard.doger@startmadrid.com
- Site Name
- Hospital Universitari Vall D Hebron
- Department Name
- Hematology Department
- Contact Person Name
- Pau Abrisqueta Costa
- Contact Person Email
- pabrisqueta@vhio.net
- Site Name
- Clinica Universidad De Navarra
- Department Name
- Hematology Department
- Contact Person Name
- Ana Alonso Piérola
- Contact Person Email
- aalfonso@unav.es
- Site Name
- Hospital Universitario 12 De Octubre
- Department Name
- Hematology Department
- Contact Person Name
- Tycho Baumann
- Contact Person Email
- tycho.baumann@gmail.com
- Site Name
- Hospital Universitari Vall D Hebron
- Department Name
- Oncology department
- Contact Person Name
- Irene Braña García
- Contact Person Email
- ibrana@vhio.net
- Site Name
- Clinica Universidad De Navarra
- Department Name
- Hematology Department
- Contact Person Name
- Miguel Angel Canales
- Contact Person Email
- macanales@unav.es
- Site Name
- Hospital Clinic De Barcelona
- Department Name
- Hematology Department
- Contact Person Name
- Andrea Rivero Arango
- Contact Person Email
- anrivero@clinic.cat
- Site Name
- Hospital Universitario De Salamanca
- Department Name
- Hematology Department
- Contact Person Name
- Norma Gutierrez Gutierrez
- Contact Person Email
- normagu@usal.es
Sponsor
Primary sponsor
- Full Name
- Janssen Cilag International
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- Belgium
Related trials
Other published trials that may interest you.
- GDC-9545 for Locally advanced or metastatic estrogen receptor-positive breast cancer
- Abemaciclib for Stage IV lung cancer | Breast cancer
- BGB-43395 for Advanced or metastatic solid tumors | Hormone receptor positive HER2 negative breast cancer
- AZD9833 for Estrogen receptor-positive HER2-negative advanced breast cancer
- Pembrolizumab for Classical Hodgkin lymphoma | Melanoma | Solid tumours (MSI-H/dMMR) | Solid tumours (TMB-H)